US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CERo Therapeutics Holdings, Inc.

9.35

-0.1100-1.16%

Volume:27.42K

Turnover:257.91K

Market Cap:4.83M

PE:0.00

High:9.57

Open:9.35

Low:9.35

Close:9.46

Loading ...

Overview Company News Filings

CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors

CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing

CERo enters manufacturing agreement with University of California Davis

Cero Therapeutics Holdings Inc - on Track for First Patient Dosing in H1 2025

THOMSON REUTERS

CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting

Cero Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement With Contract Research Organization Cellcarta to Manage Translational Assays

THOMSON REUTERS

CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays

CERo Therapeutics Holdings, Inc. Highlights Progress

Cero Therapeutics prices $5M at-the-market offering

BRIEF-Cero Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Cero Therapeutics Announces $5 Million Public Offering Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS

Cero Therapeutics Holdings Inc - Prices Public Offering at $1.96 per Share

THOMSON REUTERS

Cero Therapeutics Holdings Inc - on Jan 17, Nasdaq Grants Cero Therapeutics Extension to Regain Compliance Until April 22, 2025

THOMSON REUTERS

Cero Therapeutics Files for Offering up to 4 Mln Shares of Common Stock Together With 4 Mln New Common Warrants

THOMSON REUTERS

CERO Stock trading halted, news pending

Cero Therapeutics to effect 1-for-100 reverse stock split

BRIEF-Cero Therapeutics Holdings Announces Reverse Stock Split

Cero Therapeutics Holdings, Inc. Announces Reverse Stock Split

THOMSON REUTERS

Cero Therapeutics Holdings Inc - Announces One-for-One Hundred Reverse Stock Split

THOMSON REUTERS

CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CERO/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CERO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CERO\",,,,,undefined,":{"symbol":"CERO","market":"US","secType":"STK","nameCN":"CERo Therapeutics Holdings, Inc.","latestPrice":9.35,"timestamp":1751558556774,"preClose":9.46,"halted":0,"volume":27416,"delay":0,"floatShares":317500,"shares":516100,"eps":-11135.544,"marketStatus":"Trading","change":-0.11,"latestTime":"07-03 12:02:51 EDT","open":9.35,"high":9.565,"low":9.35,"amount":257908.699928,"amplitude":0.022727,"askPrice":9.5,"askSize":400,"bidPrice":9.36,"bidSize":25,"shortable":3,"etf":0,"ttmEps":-11135.544,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1751562000000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":9.46,"preHourTrading":{"tag":"盘前","latestPrice":9.47,"preClose":9.46,"latestTime":"09:28 EDT","volume":497,"amount":4699.9302,"timestamp":1751549280038},"postHourTrading":{"tag":"盘后","latestPrice":9.36,"preClose":9.46,"latestTime":"19:59 EDT","volume":310,"amount":2892.8625,"timestamp":1751500790017},"volumeRatio":0.434388},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CERO\",,,,,undefined,":{"symbol":"CERO","floatShares":317500,"roa":"-122.86%","roe":"--","lyrEps":-15538.9768,"volumeRatio":0.434388,"shares":516100,"dividePrice":0,"high":9.565,"amplitude":0.022727,"preClose":9.46,"low":9.35,"week52Low":6.71,"pbRate":"-1.75","week52High":895.4,"institutionHeld":0,"latestPrice":9.35,"committee":-0.882353,"eps":-11135.544,"divideRate":0,"volume":27416,"delay":0,"ttmEps":-11135.544,"open":9.35,"prevYearClose":120,"prevWeekClose":9.55,"prevMonthClose":9.63,"prevQuarterClose":9.63,"fiveDayClose":10.68,"twentyDayClose":9,"sixtyDayClose":14.2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CERO\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2523794667","title":"CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2523794667","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523794667?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:15","pubTimestamp":1743423300,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., March 31, 2025  -- CERo Therapeutics Holdings, Inc.,   an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that the Company has received clearance by the U.S. Food and Drug Administration  for a second Investigational New Drug  application for lead compound CER-1236 for a Phase 1 clinical trial in advanced solid tumors, specifically non-small cell lung cancer and ovarian cancer.CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cero-therapeutics-holdings-inc-receives-121500567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","CERO","CEROW"],"gpt_icon":0},{"id":"2522708653","title":"CERo Therapeutics Holdings, Inc.  Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522708653","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522708653?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:15","pubTimestamp":1743077700,"startTime":"0","endTime":"0","summary":"Company reports acceptance of an abstract at the 2025 American Society of Clinical Oncology  conference; Continues to be on track to dose first patient in first half of 2025. SOUTH SAN FRANSCISCO, Calif., March 27, 2025  -- CERo Therapeutics Holdings, Inc.,   an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that the Company has received positive review from the U.S. Food and Drug Administration  on an amendment to its IND around Chemistry, Manufacturing and Controls , which marks completion of the Company’s final commitment to FDA prior to initiating patient dosing and shortens the manufacturing timeline by about a week. With this completion, the Company is on track to meet its anticipated timeline of dosing initial subjects during the first half of 2025.CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the tr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cero-therapeutics-holdings-inc-poised-121500919.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CR","IE00BHPRN162.USD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU0267386448.USD","LU1363072403.SGD","CMC","CEROW","CERO","LU0149725797.USD","LU0882574139.USD","BK4006","PK","BK4161","BK4218","LU0170899867.USD","ORR","IE00B1BXHZ80.USD","BK4181","LU0971096721.USD"],"gpt_icon":0},{"id":"2520186152","title":"CERo enters manufacturing agreement with University of California Davis","url":"https://stock-news.laohu8.com/highlight/detail?id=2520186152","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520186152?lang=en_us&edition=fundamental","pubTime":"2025-03-19 20:20","pubTimestamp":1742386849,"startTime":"0","endTime":"0","summary":"CERo Therapeutics (CERO) announces an agreement with the University of California Davis for the manufacturing of CER-1236 to be used in the Company...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cero-enters-manufacturing-agreement-with-university-of-california-davis?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cero-enters-manufacturing-agreement-with-university-of-california-davis?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2520855011","title":"Cero Therapeutics Holdings Inc - on Track for First Patient Dosing in H1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2520855011","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520855011?lang=en_us&edition=fundamental","pubTime":"2025-03-19 20:15","pubTimestamp":1742386500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nTUA36LZ9D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2519315839","title":"CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2519315839","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519315839?lang=en_us&edition=fundamental","pubTime":"2025-03-13 20:15","pubTimestamp":1741868100,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANSCISCO, Calif., March 13, 2025  -- CERo Therapeutics Holdings, Inc.,   an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it is presenting encouraging preclinical results of lead compound CER-1236 in ovarian cancer during the 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors in San Diego, March 12-14.In the poster, titled, “TIM-4-L Expression on Ovarian Cancer Samples can be Targeted by Engineered Chimeric Engulfment Receptor T cells without Toxicity,” investigators demonstrated that CER-1236treated ovarian cancer cells and did not generate toxicity in animal models . Investigators found that following dosing, assessment of clinical and anatomic pathology after CER-1236 infusion showed T cell engraftment in lymphoid organs, but there were no in-life observations, clinical pathology, nor histopathological evaluations indicating toxicity caused by the compound.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cero-therapeutics-holdings-inc-presents-121500350.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CERO","CEROW"],"gpt_icon":0},{"id":"2517315267","title":"Cero Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement With Contract Research Organization Cellcarta to Manage Translational Assays","url":"https://stock-news.laohu8.com/highlight/detail?id=2517315267","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517315267?lang=en_us&edition=fundamental","pubTime":"2025-03-06 21:15","pubTimestamp":1741266926,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nFWN3PP0GH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2517152714","title":"CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays","url":"https://stock-news.laohu8.com/highlight/detail?id=2517152714","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517152714?lang=en_us&edition=fundamental","pubTime":"2025-03-06 21:15","pubTimestamp":1741266900,"startTime":"0","endTime":"0","summary":"Company continues toward the initiation of its Phase 1 Clinical Trial in AML for CER-1236. CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells . CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor  cell therapy, as the use of CER-T may potentiall","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cero-therapeutics-holdings-inc-announces-131500341.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CERO","BK4097","BK4139","CEROW","PRGS","LU2065732104.USD"],"gpt_icon":0},{"id":"2509275525","title":"CERo Therapeutics Holdings, Inc. Highlights Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2509275525","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509275525?lang=en_us&edition=fundamental","pubTime":"2025-02-06 21:15","pubTimestamp":1738847700,"startTime":"0","endTime":"0","summary":"Increased cash balance and momentum with both Nasdaq and Phase 1 trial initiation mark strong beginning for 2025. CEO Chris Ehrlich commented, “We have had a very strong entry into 2025, which has greatly improved the outlook of the Company from the previous year. As announced, we completed a $5 million financing, which gives us a current cash position of approximately $8 million. We believe this funding will allow us to achieve numerous value-creating milestones in the coming year. In addition, we have also completed the conversion of the majority of our preferred shares into common shares, which significantly improves our cap table moving forward.CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is desig","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cero-therapeutics-holdings-inc-highlights-131500688.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CERO","BK4139","PRGS","CEROW","BK4097","LU2065732104.USD"],"gpt_icon":0},{"id":"2509260414","title":"Cero Therapeutics prices $5M at-the-market offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2509260414","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509260414?lang=en_us&edition=fundamental","pubTime":"2025-02-06 09:40","pubTimestamp":1738806043,"startTime":"0","endTime":"0","summary":"CERo Therapeutics (CERO) announced the pricing of its “reasonable best efforts” public offering with participation from a member of the Company’s b...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cero-therapeutics-prices-5m-at-the-market-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cero-therapeutics-prices-5m-at-the-market-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","CERO","BK4139"],"gpt_icon":0},{"id":"2509264124","title":"BRIEF-Cero Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2509264124","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509264124?lang=en_us&edition=fundamental","pubTime":"2025-02-06 09:01","pubTimestamp":1738803665,"startTime":"0","endTime":"0","summary":"BRIEF-Cero Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq RulesFeb 5 (Reuters) - CERo Therapeutics Holdings Inc CERO.O:CERO THERAPEUTICS ANNOUNCES $5 MILLION PUBLI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250206:nTUA4NVVSC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CERO"],"gpt_icon":0},{"id":"2509264369","title":"Cero Therapeutics Announces $5 Million Public Offering Priced at-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2509264369","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509264369?lang=en_us&edition=fundamental","pubTime":"2025-02-06 09:00","pubTimestamp":1738803600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250206:nTUA4NVVSC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2509126492","title":"Cero Therapeutics Holdings Inc - Prices Public Offering at $1.96 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2509126492","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509126492?lang=en_us&edition=fundamental","pubTime":"2025-02-06 09:00","pubTimestamp":1738803600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250206:nTUA4NVVSC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CERO"],"gpt_icon":0},{"id":"2505224592","title":"Cero Therapeutics Holdings Inc - on Jan 17, Nasdaq Grants Cero Therapeutics Extension to Regain Compliance Until April 22, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2505224592","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505224592?lang=en_us&edition=fundamental","pubTime":"2025-01-21 20:33","pubTimestamp":1737462825,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250121:nFWN3OH0O3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2505322375","title":"Cero Therapeutics Files for Offering up to 4 Mln Shares of Common Stock Together With 4 Mln New Common Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2505322375","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505322375?lang=en_us&edition=fundamental","pubTime":"2025-01-21 19:27","pubTimestamp":1737458855,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250121:nFWN3OH0NK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2501763335","title":"CERO Stock trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2501763335","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501763335?lang=en_us&edition=fundamental","pubTime":"2025-01-08 08:50","pubTimestamp":1736297426,"startTime":"0","endTime":"0","summary":"19:50 EST CERO Stock trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breaking financial n...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cero-stock-trading-halted-news-pending?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cero-stock-trading-halted-news-pending?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2501661209","title":"Cero Therapeutics to effect 1-for-100 reverse stock split","url":"https://stock-news.laohu8.com/highlight/detail?id=2501661209","media":"TipRanks","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501661209?lang=en_us&edition=fundamental","pubTime":"2025-01-07 21:13","pubTimestamp":1736255593,"startTime":"0","endTime":"0","summary":"CERo Therapeutics  announced that its board of directors has determined to effect a one-for-one hundred reverse stock split of the Company’s common stock, par value $0.0001 per share. The reverse stock split will take effect at 12:01 a.m. Eastern Time on January 8, 2025, and the Company’s Common Stock will begin trading on a split-adjusted basis on The Nasdaq Global Market as of the opening of trading on January 8, 2025. The CUSIP number of 71902K303 will be assigned to the Company’s Common Stock when the reverse stock split becomes effective. When the reverse stock split becomes effective, every one hundred of the Company’s issued shares of Common Stock will be combined into one issued share of Common Stock, without any change to the par value per share. This will reduce the number of outstanding shares of Common Stock from approximately 260 million shares to approximately 2.6 million shares.Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Cero Therapeutic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/cero-therapeutics-effect-1-100-131313162.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cero-therapeutics-effect-1-100-131313162.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CEROW","LENZ","BK4139","CERO"],"gpt_icon":0},{"id":"2501239993","title":"BRIEF-Cero Therapeutics Holdings Announces Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2501239993","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501239993?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:04","pubTimestamp":1736168695,"startTime":"0","endTime":"0","summary":"Jan 6 (Reuters) - CERo Therapeutics Holdings Inc :   * CERO THERAPEUTICS HOLDINGS, INC. ANNOUNCES REVERSE STOCK SPLIT   * CERO THERAPEUTICS HOLDINGS INC - ANNOUNCES ONE-FOR-ONE HUNDRED REVERSE STOCK SPLITSource text:   Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","CERO"],"gpt_icon":0},{"id":"2501423933","title":"Cero Therapeutics Holdings, Inc. Announces Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2501423933","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501423933?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:00","pubTimestamp":1736168401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nTUA19JL85:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2501396542","title":"Cero Therapeutics Holdings Inc - Announces One-for-One Hundred Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2501396542","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501396542?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:00","pubTimestamp":1736168401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nTUA19JL85:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CERO"],"gpt_icon":0},{"id":"2501239660","title":"CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2501239660","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501239660?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:00","pubTimestamp":1736168400,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANSCISCO, Calif., Jan. 06, 2025  -- CERo Therapeutics Holdings, Inc.,   an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, today announced that its board of directors has determined to effect a one-for-one hundred reverse stock split of the Company’s common stock, par value $0.0001 per share .The reverse stock split will take effect at 12:01 a.m. Eastern Time on January 8, 2025, and the Company’s Common Stock will begin trading on a split-adjusted basis on The Nasdaq Global Market  as of the opening of trading on January 8, 2025. The CUSIP number of 71902K303 will be assigned to the Company’s Common Stock when the reverse stock split becomes effective.The reverse stock split ratio approved by the board of directors is within the previously disclosed range of ratios for a reverse stock s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cero-therapeutics-holdings-inc-announces-130000155.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NVIW.SI","QLD","PSQ","CEROW","QID","NQmain","TQQQ","MNQmain","TSYW.SI","USJW.SI","SQQQ","CERO",".IXIC","USAW.SI"],"gpt_icon":1}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":60,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CERO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-06-13","symbol":"CERO","defaultRemindTime":1749821400000,"type":"split","dateTimestamp":1749787200000,"forFactor":20,"toFactor":1,"ratio":20},{"market":"US","date":"2025-01-08","symbol":"CERO","defaultRemindTime":1736346600000,"type":"split","dateTimestamp":1736312400000,"forFactor":100,"toFactor":1,"ratio":100},{"market":"US","date":"2024-02-15","symbol":"CERO","reason":null,"defaultRemindTime":1708007400000,"announcedDate":"2024-02-14","type":"delisting","dateTimestamp":1707973200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CERO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CERO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1750737600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CERO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CERO","date":"2025-07-02","current":-0.320749,"percent":0.873457,"low":-23.40166,"twenty":-6.78571,"median":-1.72898,"eighty":-0.475494,"high":-0.137942,"avg":-3.920794,"sd":4.865033,"marketCap":3563730},"quantilePoints":[{"date":"2024-02-23","current":-14.247617,"twenty":-20.956561,"median":-17.613942,"eighty":-14.944588,"marketCap":35849112},{"date":"2024-03-01","current":-17.506812,"twenty":-18.431546,"median":-15.409236,"eighty":-15.153206,"marketCap":44049729},{"date":"2024-03-08","current":-18.247371,"twenty":-17.820809,"median":-15.409236,"eighty":-15.203159,"marketCap":45913085},{"date":"2024-03-15","current":-13.270815,"twenty":-17.820809,"median":-15.409236,"eighty":-15.057448,"marketCap":33391335},{"date":"2024-03-22","current":-12.856102,"twenty":-17.518661,"median":-15.34438,"eighty":-13.839564,"marketCap":32347855},{"date":"2024-03-28","current":-9.656887,"twenty":-17.423869,"median":-15.187199,"eighty":-12.785008,"marketCap":24298158},{"date":"2024-04-05","current":-11.26226,"twenty":-17.423869,"median":-15.107401,"eighty":-12.559878,"marketCap":28563716},{"date":"2024-04-12","current":-10.85589,"twenty":-17.252059,"median":-14.262796,"eighty":-11.529063,"marketCap":27533066},{"date":"2024-04-19","current":-8.940145,"twenty":-16.820909,"median":-13.270815,"eighty":-10.646899,"marketCap":22674290},{"date":"2024-04-26","current":-8.185457,"twenty":-16.072132,"median":-12.878911,"eighty":-10.171589,"marketCap":20760226},{"date":"2024-05-03","current":-8.011298,"twenty":-15.61915,"median":-12.441389,"eighty":-9.218799,"marketCap":20318519},{"date":"2024-05-10","current":-6.676082,"twenty":-15.409236,"median":-11.944081,"eighty":-8.208678,"marketCap":16932099},{"date":"2024-05-17","current":-6.559976,"twenty":-15.406992,"median":-11.26226,"eighty":-8.011298,"marketCap":16637628},{"date":"2024-05-24","current":-5.773123,"twenty":-15.356229,"median":-10.681731,"eighty":-7.83714,"marketCap":13841623},{"date":"2024-05-31","current":-6.030941,"twenty":-15.281507,"median":-10.409864,"eighty":-6.954736,"marketCap":14459767},{"date":"2024-06-07","current":-4.748738,"twenty":-15.235078,"median":-10.159255,"eighty":-6.68061,"marketCap":11385560},{"date":"2024-06-14","current":-2.25909,"twenty":-15.107401,"median":-9.656887,"eighty":-6.509425,"marketCap":5416387},{"date":"2024-06-21","current":-1.821847,"twenty":-15.007495,"median":-8.940145,"eighty":-6.069835,"marketCap":4368054},{"date":"2024-06-28","current":-1.912311,"twenty":-14.84161,"median":-8.707933,"eighty":-5.984352,"marketCap":4584951},{"date":"2024-07-05","current":-1.595686,"twenty":-14.277975,"median":-8.24351,"eighty":-5.773123,"marketCap":3825813},{"date":"2024-07-12","current":-1.228176,"twenty":-14.247617,"median":-8.069351,"eighty":-4.748738,"marketCap":2944671},{"date":"2024-07-15","current":-1.226291,"twenty":-14.24184,"median":-8.069351,"eighty":-4.719086,"marketCap":2940152},{"date":"2024-08-02","current":-1.013952,"twenty":-14.236062,"median":-8.040325,"eighty":-4.535268,"marketCap":2431048},{"date":"2024-08-09","current":-0.885794,"twenty":-13.839564,"median":-8.011298,"eighty":-2.310102,"marketCap":2123778},{"date":"2024-08-16","current":-0.654013,"twenty":-13.158247,"median":-7.83714,"eighty":-1.891957,"marketCap":2229214},{"date":"2024-08-23","current":-2.636712,"twenty":-12.954324,"median":-7.140505,"eighty":-1.844463,"marketCap":7260829},{"date":"2024-08-30","current":-2.420589,"twenty":-12.883473,"median":-6.744599,"eighty":-1.891957,"marketCap":6665683},{"date":"2024-09-06","current":-2.068131,"twenty":-12.832404,"median":-6.687402,"eighty":-1.924373,"marketCap":5695102},{"date":"2024-09-13","current":-1.60378,"twenty":-12.678367,"median":-6.559976,"eighty":-1.829704,"marketCap":4416400},{"date":"2024-09-20","current":-1.622429,"twenty":-12.393993,"median":-6.417311,"eighty":-1.725453,"marketCap":4467754},{"date":"2024-09-27","current":-1.758564,"twenty":-12.190139,"median":-6.030941,"eighty":-1.729099,"marketCap":4842634},{"date":"2024-10-04","current":-1.723131,"twenty":-12.057464,"median":-5.826769,"eighty":-1.723525,"marketCap":4745063},{"date":"2024-10-11","current":-1.770191,"twenty":-11.67976,"median":-5.685419,"eighty":-1.725453,"marketCap":4874653},{"date":"2024-10-18","current":-1.640939,"twenty":-11.355145,"median":-5.192459,"eighty":-1.725453,"marketCap":4518726},{"date":"2024-10-25","current":-4.541316,"twenty":-11.227428,"median":-4.704227,"eighty":-1.717164,"marketCap":12505622},{"date":"2024-10-31","current":-4.448525,"twenty":-11.088102,"median":-4.448525,"eighty":-1.723131,"marketCap":12250098},{"date":"2024-11-08","current":-3.853568,"twenty":-10.85589,"median":-4.424907,"eighty":-1.725101,"marketCap":10611741},{"date":"2024-11-15","current":-10.217961,"twenty":-11.088102,"median":-4.448525,"eighty":-1.726861,"marketCap":28137649},{"date":"2024-11-22","current":-5.605162,"twenty":-11.378366,"median":-4.622772,"eighty":-1.72898,"marketCap":37261342},{"date":"2024-11-29","current":-5.285991,"twenty":-11.285481,"median":-4.70795,"eighty":-1.736236,"marketCap":29010326},{"date":"2024-12-06","current":-5.244908,"twenty":-11.122934,"median":-4.743697,"eighty":-1.739542,"marketCap":28784857},{"date":"2024-12-13","current":-1.906243,"twenty":-10.902332,"median":-4.70795,"eighty":-1.744391,"marketCap":10461755},{"date":"2024-12-20","current":-1.478982,"twenty":-10.729812,"median":-4.535858,"eighty":-1.726509,"marketCap":8116878},{"date":"2024-12-27","current":-2.097767,"twenty":-10.58386,"median":-4.43215,"eighty":-1.724313,"marketCap":11512866},{"date":"2025-01-03","current":-2.13273,"twenty":-10.499069,"median":-4.417664,"eighty":-1.725805,"marketCap":11704747},{"date":"2025-01-10","current":-1.293623,"twenty":-10.455734,"median":-4.2029,"eighty":-1.723525,"marketCap":7099600},{"date":"2025-01-17","current":-0.870573,"twenty":-10.310323,"median":-4.062655,"eighty":-1.649339,"marketCap":4777839},{"date":"2025-01-24","current":-0.821625,"twenty":-10.217961,"median":-3.965464,"eighty":-1.627827,"marketCap":4509205},{"date":"2025-01-31","current":-0.695759,"twenty":-10.19009,"median":-3.820818,"eighty":-1.596315,"marketCap":3818433},{"date":"2025-02-07","current":-0.713241,"twenty":-10.159255,"median":-2.907717,"eighty":-1.573503,"marketCap":3914374},{"date":"2025-02-14","current":-0.62933,"twenty":-10.101202,"median":-2.636712,"eighty":-1.510537,"marketCap":3453859},{"date":"2025-02-21","current":-0.716737,"twenty":-9.74575,"median":-2.540899,"eighty":-1.377788,"marketCap":3933562},{"date":"2025-02-28","current":-0.562901,"twenty":-9.640801,"median":-2.437302,"eighty":-1.224909,"marketCap":3089285},{"date":"2025-03-07","current":-0.510457,"twenty":-9.079472,"median":-2.372103,"eighty":-1.030709,"marketCap":2801464},{"date":"2025-03-14","current":-0.335713,"twenty":-8.754375,"median":-2.239137,"eighty":-0.96912,"marketCap":1842442},{"date":"2025-03-21","current":-0.335643,"twenty":-8.503123,"median":-2.198781,"eighty":-0.896348,"marketCap":1842058},{"date":"2025-03-28","current":-0.267465,"twenty":-8.285192,"median":-2.14239,"eighty":-0.857987,"marketCap":1467890},{"date":"2025-04-04","current":-0.24439,"twenty":-8.197068,"median":-2.097767,"eighty":-0.804927,"marketCap":1341248},{"date":"2025-04-11","current":-0.269213,"twenty":-8.092572,"median":-2.074831,"eighty":-0.719534,"marketCap":1477484},{"date":"2025-04-17","current":-0.137942,"twenty":-8.069351,"median":-2.037496,"eighty":-0.697857,"marketCap":1145530},{"date":"2025-04-25","current":-0.719207,"twenty":-8.034519,"median":-1.993365,"eighty":-0.682473,"marketCap":5972602},{"date":"2025-05-02","current":-0.577828,"twenty":-8.011298,"median":-1.936658,"eighty":-0.655985,"marketCap":4798528},{"date":"2025-05-09","current":-0.472927,"twenty":-8.011298,"median":-1.906243,"eighty":-0.642767,"marketCap":3927389},{"date":"2025-05-16","current":-0.378199,"twenty":-7.976467,"median":-1.862996,"eighty":-0.625834,"marketCap":3140728},{"date":"2025-05-23","current":-0.254249,"twenty":-7.883582,"median":-1.835754,"eighty":-0.593155,"marketCap":2824879},{"date":"2025-05-30","current":-0.250375,"twenty":-7.83714,"median":-1.821847,"eighty":-0.577167,"marketCap":2781833},{"date":"2025-06-06","current":-0.207274,"twenty":-7.721034,"median":-1.77581,"eighty":-0.547912,"marketCap":2302949},{"date":"2025-06-13","current":-0.273488,"twenty":-7.384327,"median":-1.751459,"eighty":-0.512702,"marketCap":3038630},{"date":"2025-06-20","current":-0.399633,"twenty":-7.094063,"median":-1.745839,"eighty":-0.507659,"marketCap":4440184},{"date":"2025-06-27","current":-0.371137,"twenty":-6.877648,"median":-1.738983,"eighty":-0.492098,"marketCap":4123580},{"date":"2025-07-02","current":-0.320749,"twenty":-6.78571,"median":-1.72898,"eighty":-0.475494,"marketCap":3563730}],"updateTime":1751558571557}}}